MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy

Neupane, Manish; Clark, Allison P.; Landini, Serena; Birkbak, Nicolai Juul; Eklund, Aron Charles; Lim, Elgene; Culhane, Aedin C.; Barry, William T.; Schumacher, Steven E.; Beroukhim, Rameen; Szallasi, Zoltan Imre; Vidal, Marc; Hill, David E.; Silver, Daniel P.

Published in:
Cancer Discovery

Link to article, DOI:
10.1158/2159-8290.cd-15-0341

Publication date:
2016

Document Version
Peer reviewed version

Link back to DTU Orbit

Citation (APA):

DTU Library
Technical Information Center of Denmark

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
MECP2 is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy

Authors/Affiliation

Manish Neupane1,2, Allison P. Clark1,2, Serena Landini1, Nicolai J. Birkbak3, Aron C. Eklund3, Elgene Lim4, Aedin C. Culhane5, William T. Barry5, Steven E. Schumacher1,6, Rameen Beroukhim1,2,6,7, Zoltan Szallasi3,8, Marc Vidal1,9,10, David E. Hill1,9,10, Daniel P. Silver1,2,7

1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
2Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
3Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Kgs, Lyngby, Denmark
4The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
6Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
8Children’s Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, and Harvard Medical School, Boston, MA 20115
9Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA 02115, USA
10Department of Genetics, Harvard Medical School, Boston, MA 02115, USA

Running title: MECP2 is a frequently amplified oncogene that mimics RAS

Keywords: MECP2, RAS, oncogene, gene amplification, epigenetic therapy

Financial Support: This work was supported by a grant from the Cogan Family Foundation (D.P.S.), DFCI startup funds from philanthropic sources (D.P.S.), the DF/HCC SPORE in breast cancer NIH P50 CA168504-01A1, a U01HG001715 (M.V. and D.E.H.), DFCI Institute Sponsored Research (M.V. and D.E.H.), and the Ellison Foundation (Boston, MA) (M.V. and D.E.H.).

Disclosure of Potential Conflicts of Interest: MN, DEH, and DPS are inventors on a patent held by the Dana-Farber Cancer Institute related to this study.

Contact

*Corresponding author: Daniel P. Silver, Dana-Farber Cancer Institute, Smith Building, Room 868b, 450 Brookline Ave, Boston, MA 02215. Phone: 617-582-8485; Fax: 617-632-4381; E-mail: Daniel_Silver@dfci.harvard.edu
Abstract
An unbiased genome-scale screen for unmutated genes that drive cancer growth when overexpressed identified MECP2 as a novel oncogene. MECP2 resides in a region of the X-chromosome that is significantly amplified across 18% of cancers, and many cancer cell lines have amplified, overexpressed MECP2 and are dependent on MECP2 expression for growth. MECP2 copy number gain and RAS family member alterations are mutually exclusive in several cancer types. The MECP2 splicing isoforms activate the major growth factor pathways targeted by activated RAS, the MAPK and PI3K pathways. MECP2 rescued the growth of a KRASG12C-addicted cell line after KRAS down-regulation, and activated KRAS rescues the growth of an MECP2-addicted cell line after MECP2 downregulation. MECP2 binding to the epigenetic modification 5-hydroxymethylcytosine is required for efficient transformation. These observations suggest that MECP2 is a commonly amplified oncogene with an unusual epigenetic mode of action.

Statement of Significance
MECP2 is a commonly amplified oncogene in human malignancies with a unique epigenetic mechanism of action.

Introduction
Several lines of evidence suggest there are undiscovered oncogenic drivers in human cancers. For example, many recurrent amplifications found in human cancers do not contain known oncogenes, although these amplifications are clearly advantageous to tumor growth as indicated by their presence in multiple tumor types (1). Further, the recent comprehensive TCGA analysis of adenocarcinoma of the lung found significant subsets of tumors with activated MAPK or PI3K pathways without identifiable genomic alterations that explain these cancer-promoting signaling
events (2), suggesting the existence of unrecognized oncogenes. In high-grade serous ovarian cancer, 45% of the tumors in the TCGA dataset have known alterations activating PI3K/RAS signaling, but it is not apparent what alterations play this or an analogous role in the remaining 55% (3).

To search for novel oncogenes that contribute to malignant transformation when overexpressed in their wild-type form, we performed an unbiased genome-scale screen. In this screen, we employed a well-studied model system in which the combination of the SV40 early region (encoding SV40 Large and Small T antigens), hTERT, and activated RAS has been shown to be sufficient to transform a number of primary human epithelial cell types (4). Many investigations have defined the role of various oncogenes and tumor suppressors by leaving out one or more of these elements, and substituting a genetic alteration present in human cancers. In our screen, rather than substituting an individual alteration for one of these elements, we added an expression library and selected cells transformed as a result.

We generated primary breast epithelial cells (HMECs) that expressed hTERT and the SV40 early region ("N minus RAS" cells). These cells are unable to grow in an anchorage-independent fashion in soft agar, a surrogate endpoint for transformation; the addition of activated RAS to these cells allows robust soft agar growth as well as their growth as tumors in xenografts in immunocompromised mice (5). For our screen, we substituted a lentivirus-based expression library (6) for activated RAS and identified library members that allowed these cells to grow in soft agar.

We found that one of the fifteen screen hits, Methyl CpG Binding Protein 2 (MECP2), is amplified in a significant fraction of human malignancies and selected it for further study. MECP2 is an X-
linked gene, which when mutated causes the autism spectrum disorder, Rett Syndrome (7); MECP2 has no well-described role in malignancy. MECP2 encodes a protein known to exhibit epigenetic control functions. It binds methylated CpG DNA sequences (8) and attracts the Sin3a repressor and histone deacetylase complexes (9) thus maintaining local chromatin surrounding a methylated CpG island in a less active state. Recent studies show that it also acts as a transcriptional activator (10, 11), likely through binding to another epigenetic modification of DNA, 5-hydroxymethylcytosine (12).

Epigenetic processes play important roles in human cancers (13). Tumors often exhibit global DNA hypomethylation, but at the same time reveal promoter hypermethylation (14). These alterations are thought to reflect gene expression changes important for tumorigenesis, including the repression of tumor suppressors. Recent genomic analyses of human tumors have revealed cancer-specific alterations in genes encoding epigenetic modifiers, including genes whose products function in DNA methylation, histone modifications and chromatin remodeling (15). Given the importance of epigenetic processes in human cancer, attempts have been made to alter various epigenetic processes for therapeutic purposes. In general, epigenetic therapeutics such as DNA methylation inhibitors or HDAC inhibitors, alone or in combination, are thought to have beneficial effect by re-establishing the expression of tumor suppressors repressed by hypermethylation or repressive chromatin marks. In most circumstances, the identities of the tumor suppressors that may be targeted by such therapy is not known, nor are the factors that ultimately caused their repression during tumorigenesis. The observations reported below suggest another possible mechanism of action for epigenetic therapy, which is based upon targeting of the epigenetic mode of action of a dominant oncogene.
Here, we show that the two splicing isoforms of MECP2 activate distinct growth factor pathways in a manner that recapitulates the major oncogenic functions of activated RAS. The ability of MECP2 to bind the epigenetic mark 5-hydroxymethylcytosine is important for MECP2 to confer anchorage-independent growth. MECP2-overexpressing cell lines derived from human cancers are addicted to MECP2 expression, suggesting MECP2 may be useful as a therapeutic target. In sum, these experiments identify MECP2 as a previously unrecognized oncogene with an unusual epigenetic mode of action that has potential therapeutic implications.

Results

A Genome-Scale Screen Identifies MECP2 as a Potential Oncogene

Primary human mammary epithelial cells (HMECs) (16) were transduced with retroviruses expressing SV40 Large T, Small T, and hTERT (referred to here as “N minus RAS” cells). N minus RAS cells become fully transformed and capable of anchorage-independent growth with the addition of activated RAS (4, 5). To screen for new oncogenes that could substitute for activated RAS, we started with a genome-scale lentiviral expression library (6) containing over 16,000 unique open reading frames (ORFs) in an arrayed format. Twenty-one pools of approximately 800 clones each were packaged as vesicular stomatitis virus G (VSV-G) pseudotyped lentiviruses. Cells infected with the 21 pools, GFP-infected negative control cells, and HRASV12-infected positive control cells were plated in soft agar. After three weeks of growth, the positive control HRASV12-infected N minus RAS HMEC plates had numerous visible soft agar colonies, the negative control GFP-infected N minus RAS HMECs had no visible colonies, and plates from 13 of the 21 pools from the ORFeome expression library also contained visible colonies. These colonies were picked, expanded, and DNA was extracted. Library members present in these colonies were identified by PCR using primers flanking the ORF, and sequencing. Despite infection at a multiplicity of infection of 0.3 as judged by drug resistance, many of these colonies
had multiple proviruses, perhaps because of frequent silencing or low expression of many proviruses (17). To validate the ability of ORFs recovered in this screen to transform N minus RAS HMECs, lentiviruses corresponding to each ORF identified by PCR and sequencing were packaged individually and used to infected N minus RAS HMECs, and growth in soft agar was assessed.

In this manner, this screen identified 15 genes capable of conferring anchorage independent growth upon N minus RAS cells (Table S1). Of these 15 validated hits, 13 were present in only a single colony, 1 was identified in 2 colonies, and 1 was identified in 6 colonies; based on these data, the screen is far from achieving saturation. We scrutinized these 15 genes for evidence of recurrent overexpression or amplification in human cancers by interrogating publicly available databases. One screen hit, OTX2, has been previously identified as an oncogene amplified in childhood medulloblastoma (18-21), and thus served as a proof of concept that this screen could identify oncogenes that participate in transformation when overexpressed in their wild-type state. Another of the screen hits, MECP2, was selected for further study because its high rate of amplification across the TCGA collection of tumors strongly suggested relevance for human cancer. It resides in an amplicon on the long arm of the X-chromosome (Xq28) that does not contain any known oncogene.

**MECP2 is Frequently Amplified and Overexpressed in Human Cancers**

To investigate the prevalence of MECP2 amplification in human cancers, we analyzed 9221 human tumor samples from the TCGA. Figure 1A shows the overall frequency of amplification of MECP2 across a number of human cancer types in the TCGA collection determined by GISTIC (22). Q-values (false discovery rate-corrected significance of amplification frequency) below 0.25 suggest that MECP2 is significantly amplified above the background rate and that the presence of
the amplified locus is enriched by selective pressure. The q-value of the amplicon containing \textit{MECP2} across the entire TCGA collections of cancers is $2.4 \times 10^{-24}$, demonstrating clear selective pressure favoring tumor cells containing this amplicon. The significance of amplification across Xq in the entire TCGA dataset of 9221 cancers, and heat maps of amplification for selected cancer types in the TCGA collection are shown in Figure 1B. The q-value for amplification is most significant in the chromosomal region that contains MECP2 (green dotted line). The region containing \textit{MECP2} is the only amplicon on the X chromosome to have a significant q-value across all human cancers (Broad Institute TCGA Copy Number Portal, Table S2).

The effect of \textit{MECP2} amplification on \textit{MECP2} mRNA levels is assessed in Figure 1C for some cancer types with high rates of \textit{MECP2} amplification, and in Figure S1A for other cancer types. In cancer types with significant frequencies of \textit{MECP2} amplification, copy number gain of \textit{MECP2} is correlated in a highly significant manner with increased \textit{MECP2} mRNA level.

\textit{MECP2} expression is silenced on the inactive X chromosome in females (23); if the \textit{MECP2} amplicon in tumors confers selective advantage because of higher \textit{MECP2} expression, the \textit{MECP2} allele on the active X chromosome would be amplified in preference to the inactive allele in tumors arising in women. We observed a pattern of amplification that confirmed preferential amplification of the active allele in triple negative breast cancer (TNBC) and ovarian cancer (Figure S1B).

Based upon the data above, TNBC, lung, and ovarian cancer were chosen for further study. Figure 1D shows western blot analysis of whole cell lysates obtained from the cell lines with and without \textit{MECP2} amplification representing these cancer types (Table S3). We have also assayed patient derived xenografts (PDXs) (24) established from TNBCs for MECP2 overexpression by
western blot; 4 of 13 (31%) consecutive TNBC PDXs overexpressed MECP2 (Figure 1D), in accord with the 33% overall frequency of MECP2 amplification in this breast cancer subset in the TCGA collection (Figure 1A).

**MECP2 Overexpression Transforms Primary Cells Containing the SV40 Early Region and hTERT**

The MECP2 gene expresses two splicing isoforms that differ by inclusion of the second exon, resulting in a long isoform, termed e1, that consists of 21 unique amino acids at the amino terminus followed by a 477 amino acid shared region, and a short isoform, e2, that has 9 unique amino acids at the amino terminus attached to the same 477aa shared region. In most cell types, the expression of e1 is higher than that of e2 at the protein level.

The expression library used for our screen contained only the shorter MECP2 splicing isoform e2; infection of N minus RAS cells with a single lentivirus encoding MECP2 e2 induced anchorage-independent growth to an extent similar to that caused by infection with activated HRAS, while the longer isoform, e1, was inactive in this regard (Figure 2A, left). To rule out the possibility that the observed transformation of N minus RAS HMEC cells by MECP2 was attributable to some unique property of N minus RAS HMECs, we constructed N minus RAS cells from an entirely different human primary breast cell type, breast primary epithelial cells (BPECs) (25). MECP2 e2 conferred anchorage-independent growth efficiently upon N minus RAS BPECs as well, and in this cell type, MECP2 e1 was capable of conferring growth in soft agar, albeit at considerably lower efficiency than the short isoform (Figure 2A, right). Soft agar colony size in N minus RAS HMECs that express MECP2 e2 was approximately equal to that induced by activated HRAS (Figure S2A), whereas in N minus RAS BPECs, colonies induced by MECP2 e2 overexpression were larger than those induced by activated HRAS (Figure S2B). Lastly, in N minus RAS BPECs,
colonies induced by MECP2 e1 overexpression were much smaller than those induced by MECP2 e2 or activated RAS in these cells (Figure S2B).

To determine whether the expression of MECP2 was sufficient to allow growth of N minus RAS cells as tumors in nude mice, a series of N minus RAS cells infected with either of the two splicing isoforms of MECP2, both isoforms together, activated RAS, or a GFP control, were injected into the flanks of nude mice. In accord with previous results (5, 25), N minus RAS HMECs infected with a retrovirus expressing activated RAS were able to form tumors in nude mice, but N minus RAS HMECs infected with a virus encoding GFP were not. N minus RAS HMECs infected with both the long and short forms (e1 and e2) formed tumors in nude mice (Figure 2B, 2C), whereas N minus RAS HMECs infected with either isoform alone were unable to form tumors. To investigate the tumor-forming abilities of the MECP2 isoforms in a different cellular context, N minus RAS BPECs were employed. N minus RAS BPECs infected with a vector expressing activated RAS are known to be at about four orders of magnitude more tumorigenic in nude mice than are N minus RAS HMECs expressing activated RAS (25). In the context of N minus RAS BPECs, each isoform of MECP2 allowed the growth of tumors in nude mice, though N minus RAS BPECs expressing both isoforms had a higher take rate and faster tumor growth (Figure 2B, 2D).

The histology of tumors induced by MECP2 isoforms was similar to those induced by HRAS (Figure S3A, B). In accord with previously published results (25), N minus RAS HMECs expressing HRAS gave rise to invasive ductal carcinomas with significant areas of squamous differentiation (Figure S3B), while N minus RAS BPECs gave rise to tumors that were morphologically similar, but the latter contained more limited areas of squamous differentiation (Figure S3A). N minus RAS HMECs and BPECs expressing MECP2 displayed histologies similar to those seen with HRAS in the two cell types (Figure 2E, 2F); further, in the case of BPECs, there
was no histologic difference seen in tumors arising after infection with each MECP2 isoform (Figure S3A).

The Transformation Function of MECP2 is Dependent on its DNA Binding Ability
Several functional domains of MECP2 have been defined. In both MECP2 splicing isoforms, the methyl DNA-binding domain (MBD) lies near the amino-terminal end, followed by a transcription repression domain responsible for binding HDAC complexes (Figure 2G). Three separate mutations in the MBD region of the MECP2 gene, R106W, R111G, and F155S, completely eliminate DNA-binding and cause Rett Syndrome (26-28). These mutations were tested for their transforming ability in the context of the MECP2 e2 isoform. They all prevent the MECP2 e2 isoform from conferring anchorage-independent growth upon N minus RAS HMECs despite expression levels similar to wt MECP2 e2, as does a truncating mutation located in the transcription repression domain (Figure 2H, I).

The MECP2 mutation, R133C, causes a less severe form of Rett Syndrome than other mutations in the DNA binding region of MECP2 (29). R133C prevents MECP2 binding to 5-hydroxymethylcytosine (5hmC), an epigenetic mark associated with actively transcribed genes; however, it largely preserves binding to 5-methylcytosine (5mC) (12). R133C in the context of the MECP2 e2 isoform was able to confer anchorage-independent growth upon N minus RAS HMECs at only about 10% of the efficiency of wild-type MECP2 e2 despite expression levels equivalent to wt MECP2 e2 (Figure 2J). This observation suggests that binding to 5hmC, and perhaps the activation of gene expression, is important for the transforming ability of MECP2.

MECP2 and activated RAS have similar functions in human tumors
Because MECP2 was isolated in a screen in which it was able to substitute for the transformation function of activated RAS, we tested to what extent MECP2 could substitute for activated RAS in
other situations. Certain cultured human cancer cell lines that contain activating KRAS mutations are dependent upon the continued presence of KRAS for growth ("RAS addiction") (30, 31). We tested whether complementation with exogenous MECP2 could rescue growth and survival defects in such a cell line after downregulation of KRAS expression. As shown in Figure 3A, the expression of the MECP2 isoforms rescued growth substantially in a dose-dependent fashion after down-regulation of KRAS in H358, a KRASG12C -addicted lung cancer cell line, using an shRNA targeting the KRAS-3’UTR. This shRNA had been previously validated as not having significant off-target effects in this cell line (designated as “K-RasC” shRNA in (30)).

If MECP2 amplification and RAS activating mutation confer similar functions during tumorigenesis, there would be little or no selective advantage conferred by the presence of both alterations in a given tumor. Therefore, there may be fewer tumors that contain both alterations than would be predicted by chance, that is, there may be a mutual exclusivity relationship between the two alterations. We investigated the relationship of MECP2 amplification to the activation of RAS family members across human tumor types and within individual tumor types. In tumor types with the highest rates of RAS mutation, pancreatic (virtually all KRAS mutated) and colon adenocarcinoma (roughly 50% mutated RAS), there are few tumors with amplification of MECP2 (GISTIC (22) detects no MECP2-containing amplicons in those tumor types). In contrast, the cancer types with the lowest rates of RAS mutation tend to have significant numbers of cancers with MECP2 amplification; for example, ovarian and triple negative breast cancers both have RAS mutations in less than 1% of tumors, but have high rates of MECP2 amplification, 38% and 33% respectively (Figure 1A).

Uterine carcinoma demonstrates a different type of mutual exclusivity relationship. In the TCGA set of uterine carcinoma samples, there are high rates of MECP2 copy number gain (15%) and
high rates of KRAS mutation (21%), but statistically significantly fewer cases with both alterations than would be expected by chance (log odds ratio -1.215, p=0.027, Figure 3B). Uterine cancers can be subcategorized by the presence or absence of microsatellite instability, POLE mutation, and the level of copy number abnormalities (CNAs); in general, tumor with microsatellite instability or POLE mutation have high numbers of point mutations and few CNAs, while POLE wt, microsatellite stable tumors have higher CNAs (32). These subtypes of uterine cancers in the TCGA dataset were shown to vary significantly by MECP2 status (p<0.0001), such that tumors with MECP2 copy number gain or amplification were more likely to be in the CN high subtype, and less likely to be in the MSI positive subtype. Conversely, tumors with KRAS mutation were significantly less likely to be in the CN high subtype, and significantly more likely to be in the MSI positive or POLE mutated subtype (p<0.0001, See Supplemental Data: Analysis of Uterine Cancer Subtypes). Therefore, the subtypes of uterine cancer drive the mutual exclusivity of MECP2 copy number gain or amplification and KRAS mutation in uterine cancer.

There are also mutual exclusivity relationships between MECP2 copy number gain and RAS alteration in some cancer types with relatively high rates of both alterations within the same subtype. Unlike uterine carcinoma, cervical cancer does not have readily identifiable subtypes (33). There is no overlap between cases with MECP2 gain or amplification and those with KRAS mutation in the TCGA collection of cervical carcinoma, a statistically significant mutual exclusivity result (log odds ratio < -3, Fisher Exact Test, p=0.041) (Figure 3B). In this tumor type, the MAPK pathway is sometimes activated by amplification or mutation of MAPK1 (ERK2) (33). These alterations of MAPK1 are also statistically significantly mutually exclusive with MECP2 amplification (log odds ratio < -3, p=0.041), and there is no overlap between cases with MAPK1 amplification or mutational activation and cases of MECP2 gain or amplification, or KRAS
mutation (Figure 3B), strongly suggesting these alterations are functionally redundant with one another. Similarly, head and neck cancers, a group of squamous cell carcinomas, has a high percentage of cases with MECP2 copy number gain (30%) and some cases with RAS mutation or amplification. In this cancer type, there is a statistically significant mutual exclusivity between MECP2 copy number gain and the union of all RAS gene mutations and amplifications (log odds ratio -0.845, Fisher Exact Test, p=0.020) (Figure 3B), again suggesting MECP2 copy number gain and RAS activity are functionally redundant.

There are other cancer types with trends toward mutual exclusivity of RAS mutation and MECP2 amplification, for example adenocarcinoma of the lung and bladder carcinoma, but the relatively small percentage of one or the other alteration requires more cases be subject to genomic analysis to have enough power to determine if these relationships are statistically significant. Taken as a whole, across all human tumor types, within a cancer type with multiple subtypes, and within monomorphic tumor types with relatively high rates of both RAS activation and MECP2 amplification, there is a tendency for tumors to have either RAS family activating mutations or MECP2 amplification, but not both, suggesting functional redundancy.

**MECP2 Isoforms Activate Growth Factor Pathways**

Given that MECP2 is able to substitute for activated RAS in a transformation assay as well as in a RAS-addicted cell line, and the mutual exclusivity analysis above between MECP2 copy number gain and RAS alteration in several cancer types, we investigated the possibility that MECP2 isoforms activate the major RAS-induced growth factor pathways, the MAPK pathway and PI3K pathway. To investigate the state of MAPK pathway activation, the persistence of MAPK signaling after growth factor deprivation was assessed, a standard technique employed to determine if there is cell-intrinsic activation of this pathway (34, 35). The MECP2 short isoform e2, but not the
long isoform e1, prolonged the presence of phosphorylated ERK1 and ERK2 in N minus RAS HMECs after growth factor deprivation (Figure 4A and Figure S4). This effect required an intact MECP2 DNA binding domain (Figure 4B). To determine at what level along the signaling cascade the MECP2 e2 isoform activates the MAPK pathway, a cRaf affinity precipitation assay (36) was used to investigate whether MECP2 increases the amount of active, GTP-bound RAS. Figure 4C, upper panel, shows that MECP2 does not increase the amount of activated, GTP-bound RAS, suggesting that the MAPK pathway is activated by MECP2 at a level below RAS in the signaling pathway. Increased MEK phosphorylation was detected in MECP2 e2-transformed cells, as was increased phosphorylation of the downstream MAPK pathway proteins, p90RSK and ELK1 (Figure 4C bottom panel). Together, these results indicate that the short isoform of MECP2 activates the MAPK signaling pathway below RAS, but at or above the level of the MEK proteins.

To assess PI3K pathway activation, cells were deprived of growth factors and persistence of PI3K signaling monitored (Figure 4D top), or deprived of growth factors for four hours, and then stimulated with recombinant EGF for 15 minutes, and re-induction monitored (figure 4D bottom), a standard assay of PI3K pathway activation (37-42)(a timecourse of EGF treatment is shown in Figure S5). PI3K signaling as assessed by p-AKT (S473) is sustained after 5 minutes of growth factor deprivation in N minus RAS cells infected with lentiviruses expressing either MECP2 isoform or activated RAS, but not in the same cells infected with a lentivirus expressing GFP. In addition, EGF treatment of MECP2 or RAS expressing N minus RAS HMECs compared with the same cells transduced with a vector expressing GFP shows increased levels of p-AKT and activated downstream PI3K pathway proteins p-4EBP1 and p-S6. These observations are consistent with prior reports of experiments with neuronal cells demonstrating that the MECP2 long isoform e1 stimulated the PI3K pathway (43, 44). In neurons, PI3K pathway induction by
MECP2 has been shown to involve increased BDNF expression (44, 45) and/or the regulation of IGF-1 signaling (46, 47).

**Human Tumor Lines with MECP2 Overexpression Are Addicted to MECP2**

Oncogene addiction, the need for continued expression of an oncogene for maintenance of the malignant phenotype (48), is necessary for therapy directed at that oncogene to be effective. The pro-tumorigenic function of MECP2 could be necessary only during the early steps of transformation, or MECP2 could be required on an ongoing basis to exert its pro-oncogenic function. To distinguish between these possibilities, three non-small cell lung cancer (NSCLC) cell lines and three breast cancer cell lines were selected for further study. The non-small cell lung cancer cell lines, NCI-H1755 and NCI-H23, both have copy number gain of MECP2 and exhibited appreciable MECP2 expression, while NCI-H1437 did not express detectable MECP2 as assessed by western blot (Figure 1D). The two NSCLCs expressing MECP2 demonstrated significant growth inhibition in response to infection with lentiviruses bearing either of two MECP2-directed shRNAs. However, the cell line that did not express MECP2, NCI-H1437, did not reveal significant growth inhibition (Figure 4E). Similarly, two human breast cancer cell lines that have MECP2 copy number gain and expressed significant amounts of MECP2, MDA-MB-468 and BT549 (Figure 1D), revealed considerable growth inhibition when infected with either of two lentiviruses expressing shRNA directed at MECP2, while the low-expressing breast cancer cell line ZR75-1 showed little growth inhibition (Figure 4E). A number of other cell lines with high MECP2 protein expression (Figure 1D), including the breast cancer cell line BT20, and the lung cancer cell lines NCI-H2228 and NCI-H522, also show growth inhibition when MECP2 expression is inhibited (Figure S6).
To determine if the shRNA effects seen in Figure 4E are attributable to off-target effects, the lung cancer line NCI-1755 was infected with lentiviruses encoding GFP, the cDNA of the MECP2 short isoform e2, the cDNA of the MECP2 long isoform e1, or viruses encoding the cDNA of both isoforms. These cell lines were then infected with a lentivirus expressing an shRNA targeting the 3’ UTR of MECP2, which downregulates both endogenous isoforms of MECP2 (Figure 4E) but would not be expected to downregulate expression of the cDNAs. Figure 4F shows that the long isoform of MECP2 did not rescue the inhibition of proliferation of NCI-H1755 caused by sP2-3’UTR, the short isoform partially rescued proliferation, but together, both isoforms almost completely rescued the proliferation inhibition caused by shRNA-mediated down-regulation of both endogenous MECP2 isoforms, showing that the proliferative defects caused by this shRNA in Figure 4E are not a result of off-target effects.

We sought to determine if activated RAS could substitute for MECP2 in an MECP2-addicted cell line. We found that expression of activated KRASG12V in the MECP2-addicted triple negative breast cancer cell line MDAMB468 substantially rescued the growth inhibition seen upon downregulation of MECP2 (Figure 4G). Thus, MECP2 can rescue the growth of cell line addicted to activated RAS after RAS downregulation (Figure 3A), and activated RAS can rescue the growth of a cell line addicted to MECP2 after MECP2 downregulation (Figure 4G), demonstrating the complementary relationship between RAS activity and MECP2 function.

Discussion

MECP2 is a Frequently Amplified Oncogene with a Unique Mechanism of Action
A genome-scale screen identified MECP2 as a gene that substitutes for activated RAS to allow anchorage-independent growth. MECP2 is frequently amplified in a number of human tumor
types, and many cell lines derived from human tumors have MECP2 amplification and overexpression. Expression of MECP2 rescues growth of a human tumor line addicted to activated RAS after down-regulation of RAS expression, and activated RAS rescues an MECP2-addicted cell line after MECP2 downregulation. MECP2 induces the MAPK and PI3K growth factor signaling pathways in common with activated RAS. MECP2 requires DNA binding for growth factor signaling and transformation, and is heavily dependent on binding to the epigenetic modification 5-hydroxycytosine for these activities. In one cellular context, the two splicing isoforms of MECP2 have quite distinct activities despite substantial sequence identity, with the shorter e2 splicing isoform allowing anchorage-independent growth and activating both the MAPK and PI3K pathways, and the longer e1 isoform activating the PI3K pathway but not enabling anchorage-independent growth on its own. Together, the two splicing isoforms allowed efficient growth of xenografts in nude mice. These findings indicate that MECP2 may function as an oncogene with an unusual epigenetic mechanism of action across a substantial number of human tumors.

The Amplification of Genes on the X Chromosome is a Potent Mechanism of Increasing Gene Expression

MECP2 is not an escape gene; it is silenced on the inactive X chromosome in females (23). The amplification of this class of X-linked genes affects gene expression more potently than amplification of other genes on a per copy basis. This effect results from the fact that in males, and after X-inactivation in females, there is only one active copy of this class of genes. For example, on average, one extra active copy of such an X-linked gene results in 200% of the normal level of expression, while in comparison, a biallelically expressed autosomal gene with one extra copy is expressed at 150% of normal levels. Three extra active copies of an X-linked gene would be expected to result in 4x the normal level of expression, while an autosomal gene
with three extra copies has only 2.5x the normal level of expression. Thus, relatively modest amplification of MECP2 that affect the active allele may have a relatively large effect on expression levels.

**Autism and Growth Factor Pathways**

Our screen linked wild-type MECP2 overexpression to transformation. Inherited loss of function mutations in MECP2 are known to be responsible for the autism spectrum disorder, Rett Syndrome (7). Though this relationship may seem surprising, the explanation may lie in connections between alterations in growth factor pathways and autism that are becoming increasingly apparent. A number of germline alterations that either increase or decrease growth factor pathway activity predispose to autism (reviewed in (49)). For example, there is a significant overrepresentation of autism among patients with Beckwith-Wiedemann syndrome (in which patients overexpress IGF2 or cyclin-dependent kinase inhibitor 1C) (50), in Neurofibromatosis (NF1) (51, 52), in the PTEN hamartoma tumor syndromes Cowden Syndrome and Bannayan-Riley-Ruvalcaba (53-57), in tuberous sclerosis (58), and SNPs for three PI3K signaling pathway genes, INPP1, PIK3CG, and TSC2, are in linkage disequilibrium with autism (59). A c-MET promoter SNP that decreases cMET expression is associated with two-fold increase in autism risk (60). Mutations in the RAS pathway scaffolding protein, CNKSR2, are associated with an autism-like disorder (61). Finally, treatment with recombinant IGF1, which crosses the blood-brain barrier and activates growth factor signaling, has been shown to have therapeutic efficacy in a mouse model of Rett Syndrome (62) and in a phase 1 clinical trial treating girls with MECP2 mutations (63).

It is not clear how defects in MECP2 lead to Rett Syndrome. Given the connection between autism spectrum disorders and growth factor pathway alterations, and our demonstration that the two...
splicing isoforms of MECP2 each contribute to the activation of growth factor pathways, the work described here may indirectly lead to further hypotheses regarding the role of abnormal growth factor pathway activation in patients with autism spectrum disorders. Further, it is tempting to speculate that the MECP2 isoform-specific differences in growth factor pathway induction demonstrated here may have arisen to titrate and balance the activity of different growth factor pathways by the process of alternative splicing in neurons. Because the growth factor pathways induced by MECP2 activity, the MAPK and PI3K pathways, are key pathways in human tumors, it seems likely that cells overexpressing MECP2 by amplification or other means would have a selective advantage during tumorigenesis.

**Epigenetic and Other Therapies**

Experiments presented here demonstrate that several human tumor cell lines with overexpressed MECP2 show significant growth impairment after MECP2 down-regulation by shRNA. These observations suggest that patients with tumors overexpressing MECP2 might benefit from therapy targeting MECP2 function. Further, the necessity of DNA binding activity of MECP2 for transformation and growth factor pathway induction suggests that interfering with the ability of MECP2 to bind DNA might have therapeutic effect. Because MECP2 binds specifically to methylated or hydroxymethylated cytosine, blocking the formation of these modified cytosines might specifically inhibit MECP2-transformed cells. The FDA-approved drugs 5-azacytidine and decitabine inhibit DNA methylation and therefore inhibit the formation of 5-methylcytosine and 5-hydroxymethylcytosine, and so may be therapeutic in tumors with overexpressed MECP2. Experiments are ongoing to test this hypothesis.

Data presented here implicate the binding of MECP2 to 5hmC as important for the cancer-related functions of MECP2. 5hmC is formed from 5mC by the action of the TET enzymes (64, 65). TET
is a tumor suppressor in some settings; TET2 inactivating mutations occur commonly in myelodysplasia and myeloid malignancies. Further, neomorphic oncogenic mutations have been found in the enzymes IDH1 or IDH2 in glioblastoma, AML, chondrosarcoma, and cholangiocarcinoma that result in the accumulation of (R)-2-hydroxyglutarate (66), an abnormal metabolite that inhibits the TET enzymes, as well as other 2-oxoglutarate-dependent dioxygenases. However, TET1 also possesses oncogenic activity (67). Given the dependence of the MECP2 transformation activity on 5hmC, it is possible that inhibition of the TET enzymes may inhibit the growth of MECP2-related tumors; this inhibition may be accomplished by compounds similar to (R)-2-hydroxyglutarate (68). Further insight into the mechanisms MECP2 uses to drive transformation may reveal additional therapeutic targets.

**MECP2- A Novel Oncogene**

*MECP2* has several properties that make it an unusual oncogene. First, its two splicing isoforms cooperate in tumor formation, with MAPK pathway induction contributed uniquely by the short isoform. Second, its mechanism of action requires the epigenetic modification of cytosine, including the recently discovered modification, 5-hydroxymethylcytosine. This property may provide unusual therapeutic opportunities. Lastly, *MECP2* is a member of a small class of genes that are involved in two entirely different human diseases. When mutated, *MECP2* causes Rett Syndrome, and when amplified/overexpressed, it is involved in cancer.

**Methods**

**Vectors**
Details of lentiviral and retroviral expression vectors, shRNA vectors (with target sequences), construction of mutants (including primer sequences) and cloning are provided in Supplemental Methods section.

**Virus production and transduction**

Virus particles were produced by transient co-transfection of 293T cells using 3 plasmid system (for retrovirus) or 5 plasmid system (for lentivirus) as detailed in supplementary section. Further information on transduction of target cells with cDNA viruses for overexpression studies and shRNA viruses for knock-down studies is described in related subsections of Supplemental Methods.

**Cell culture**

The HMECs were purchased from Lonza, and the BPECs were gift from Dr. Tan Ince (University of Miami) in January 2010; no authentication of these cells has been done by the authors. The BT549, MDAMB468, ZR75-1, BT20, HCC38, MCF7, MDAMB231, MDAMB453, and T47D cell lines were purchased from ATCC, and no authentication has been done by the authors. The NCI-H1755, NCI-H23, NCI-H1437, NCI-H1395, and NCI-H2347 cell lines from the Minna and Gazdar laboratories (The University of Texas Southwestern Medical Center) were provided to the Belfer Institute/Dana-Farber through the Meyerson Lab at the Broad Institute (with permission from the originators), and were obtained by authors in November 2012. The NCI-H2228, NCI-H522, NCI-H1563, NCI-H2170, and NCI-H358 cell lines were purchased from ATCC and, NCI-H2009 and NCI-H1993 cell lines were obtained from Belfer Institute in November 2012. All of these lung cancer cell lines have been short-tandem repeat (STR)-profiled and mycoplasma tested at the
Belfer Institute. The EFO21, IGROV1, SKOV3, CAOV3, OVCAR3, OVCAR4, OVCAR5, and OVCAR8 cell lines were gift from Dr. Ronny Drapkin (University of Pennsylvania) in March 2013 and have been STR-fingerprinted at Drapkin laboratory. All the cell lines employed for the experiments described in this manuscript were used from early passages (for less than 6 months) of cell stocks frozen at the time of receipt. All cell lines were maintained at 37°C with 10% CO₂. Details about culture conditions, media composition and generation and maintenance of stable cell lines are described in Supplemental Methods section.

**Soft agar growth and Tumorigenicity assay**

Anchorage-independent growth of cells in soft agar was determined by plating $3 \times 10^4$ cells (HMECs or BPECs derivatives) in 0.3% Noble agar (Difco). Colonies were counted after 3 weeks of growth. Xenograft study was carried out in NCr nude mice (Taconic), and the study protocol was approved by the Dana-Farber IACUC. For further details on both of these assays, see Supplemental Methods.

**Cell proliferation assays**

Cell proliferation was quantified by either measuring cellular ATP content by CellTiter-Glo Luminescent Cell Viability Assay (Promega), or by extracting the cell-associated crystal violet dye with 10% acetic acid.

**Western blot**

Cells were lysed in RIPA buffer and western blot was carried out using standard protocol. For assays involving MAPK pathway activity, HMEC derivatives were washed three times with PBS,
reset in growth factor-deprived medium (MEBM) at 37°C for 5 minutes or longer, and then lysed (see Supplemental Methods for details). For assays involving PI3K pathway activity, HMEC derivatives were washed three times with PBS, starved in MEBM for five minutes and analyzed, or starved for 4 hours, treated with EGF (2.5 ng/ml; Sigma) at 37°C for 15 minutes, and then lysed. Primary antibodies used for immunoblotting are listed in Supplemental Methods.

**Bioinformatic Analysis**

SNP6 array data generated by TCGA from 9221 cancers across 29 cancer types were analyzed for significantly recurrent amplifications using GISTIC 2.0 (69) and according to the methods described in (70). Further details about the samples, analysis parameters, and detailed results can be found in Broad Institute TCGA Copy Number Portal, under the analysis version “2014-07-08 stddata_2014_06_14.” For details of the expression vs. copy number and A.I. analyses, please see Supplemental Methods.

**Author Contributions**

D.P.S. conceived of the study; M.N., D.E.H., and D.P.S. designed the experiments; M.N., A.P.C. and S.L. performed the experiments; M.N., A.P.C., and D.P.S. interpreted the experiments; D.E.H. and M.V. provided the lentiviral ORFeome expression library, N.J.B., A.C.E, and Z.S. analyzed the relationship of copy number and A.I. to expression; E.L. established and provided PDX models, A.C.C., W.T.B., S.E.S. and R.B. analyzed the significance and prevalence of MECP2 amplification; D.P.S. wrote the manuscript, and all authors edited the manuscript.
Acknowledgments

We thank A. Richardson for evaluating the xenograft pathology specimens, A. MacWilliams and T. Hao for help with the lentivirus orfeome library, T. Joshi for bioinformatics analysis, D. Livingston and members of the Livingston lab for discussions and advice. We thank all of the investigators, institutions, and patients who contributed to the Cancer Genome Atlas (TCGA) research network; the results published here are in part based upon data generated by the TCGA Research Network.
References


Figure Legends

**Figure 1. MECP2 is Amplified and Overexpressed in Several Human Cancer Types**

(A) MECP2 amplification frequencies in selected cancer types are shown. Source: Broad Institute TCGA Copy Number Portal, 9221 Tumor Samples, 2014-07-08 data release.

(B) The significance of MECP2 amplifications determined by GISTIC (Genomic Identification Of Significant Targets In Cancer)(22) across 9221 cancers in the TCGA collection is shown alongside a heat map of copy number alterations of Xq in selected human cancers with MECP2 amplification. The dotted green line indicates the location of the MECP2 gene.

(C) The relationship of MECP2 expression to MECP2 copy number is shown for lung adenocarcinoma, ovarian cancer, uterine cancer, and triple negative breast cancer (TNBC) (TCGA dataset). The X axis shows the copy number in a 2mb region surrounding MECP2 minus the average copy number of the total X chromosome, the Y axis shows MECP2 RNA expression quantitated by RNAseq.

(D) Western blots of MECP2 protein expression in total cell lysates from human cell lines and Patient Derived Xenografts (PDXs) derived from TNBC. Diploid cell lines without MECP2 amplification are for comparison (top); all other samples are from human cancer cell lines and TNBC PDXs. Where known, the MECP2 copy number is in parentheses.

**Figure 2. Oncogenic Activities of MECP2 Splicing Isoforms are Distinct and Require DNA-binding**

(A) The ability of MECP2 splicing isoforms to confer anchorage-independent growth to N minus RAS HMECs and N minus RAS BPECs (a different strain of primary human breast epithelial cells) in comparison to isogenic non-transformed GFP-infected cells and
isogenic HRAS\textsuperscript{12}-transformed cells is shown. The average number of soft agar colonies from 3 replicates, +/- sd is indicated.

(B-F) N minus RAS HMECs or N minus RAS BPECs infected with viruses expressing the indicated genes were injected into the flanks of nude mice. The number of tumors observed is shown. Ten injections were performed for each cell type (B). Representative photographs of tumor-bearing nude mice injected with N minus RAS HMEC cells infected with both isoforms of \textit{MECP2} (C) or N minus RAS BPEC cells infected with both isoforms of \textit{MECP2} (D) and 40X photomicrographs of tumor H&E histology are shown from N minus RAS HMECs expressing both isoforms of \textit{MECP2} (E) or N minus RAS BPECs expressing both isoforms of \textit{MECP2} (F). Scale bars, 0.1 mm.

(G) The location of structural features and mutations in the context of the \textit{MECP2} short isoform e2.

(H) Protein expression of mutant and wt alleles in the context of \textit{MECP2} e2 from whole cell lysates of N minus RAS HMECs.

(I) Soft agar growth of N minus RAS HMECs expressing \textit{MECP2} e2 mutations that completely abrogate the ability of MECP2 to bind DNA.

(J) Soft agar colony counts for N minus RAS HMECs expressing GFP, wt \textit{MECP2} e2, or \textit{MECP2} e2 bearing the mutation R133C, which prevents MECP2 binding to 5hmC and leaves binding to 5mC largely intact. The average number of soft agar colonies from 3 replicates, +/- sd are indicated. Inset: MECP2 immunoblot of whole cell lysates prepared from cells used in soft agar assay.

\textbf{Figure 3. The Functions of MECP2 and Activated RAS are Similar in Human Cancers}
(A) The KRAS-addicted cell line H358, a cell line derived from a human adenocarcinoma of the lung, was infected with doxycycline-inducible constructs expressing the MECP2 e1 isoform, the e2 isoform, both isoforms, or with a virus expressing activated KRAS. Increasing levels of MECP2 expression were induced by the use of higher concentrations of doxycycline (shown in MECP2 immunoblot on the right). All cell lines were then infected with a virus expressing a validated shRNA targeting KRAS (shKRAS#3’UTR), and 12 days later, cell numbers were measured by quantitating ATP with the CellTiter-Glo Luminescent Cell Viability Assay. Mean ±SD data from 4 independent viral infections (n=4) were analyzed using one-way ANOVA followed by post hoc Dunnett’s multiple comparison test. Asterisks indicate statistically significant difference between each experimental group and uninfected control (****: p<0.0001, ***: p=0.0001, **: p=0.0030, *: p=0.0237, ns: non-significant, p>0.05)

(B) Graphical summary (Oncoprint) demonstrating mutual exclusivity of MECP2 amplification or copy number gain, RAS family alterations, and MAPK1 (ERK2) alterations in uterine, cervical, and head and neck cancer. The TCGA dataset (242 cases of uterine cancer, 191 cases of cervical cancer, and 302 cases of head and neck cancer with both sequencing and copy number data) were analyzed for mutual exclusivity using the cBio Portal for Cancer Genomics; p values for mutual exclusivity are indicated (Fisher Exact Test). Only tumors with alterations in the indicated genes are shown in the figure.

**Figure 4. The MECP2 Short Isoform e2 Activates The MAPK Pathway, Both MECP2 Isoforms Activate the PI3K Pathway, and Human Cancer Cell Lines with Amplified MECP2 are Addicted to MECP2 Expression**
(A, B) N minus RAS HMECs expressing the indicated genes were switched to minimal media without growth factors for five minutes (A), or twenty-four hours (B), and whole cell lysates were used for western blotting with the antibodies shown.

(C) Top Panel: Beads coupled to the ras binding domain (RBD) of CRAF were used to affinity precipitate GTP-bound RAS from cell lysates, and the precipitate was subject to immunoblotting with an antibody detecting all RAS proteins, labeled GTP-RAS; total cell lysate was used with the same antibody and are labeled Total RAS. Bottom Panel: N minus RAS HMECs expressing the indicated genes were switched to minimal media without growth factors for five minutes, and whole cell lysates were used for western blotting with the antibodies shown.

(D) Top Panel: N minus RAS HMECs expressing the indicated genes were switched to minimal media without growth factors for five minutes, and then whole cell lysates were used for western blotting with the antibodies shown. Bottom Panel: N minus RAS HMECs expressing the indicated genes were switched to minimal media without growth factors for four hours, treated with 2.5 ng/ml EGF for 15 minutes, and then whole cell lysates were used for western blotting with the antibodies shown.

(E) Upper: Two lung adenocarcinoma cell lines with MECP2 copy number gain and MECP2-overexpression, NCI-H1755 and NCI-H23, and the MECP2 non-overexpressing lung adenocarcinoma cell line NCI-H1437 (for MECP2 protein expression in these lines, see Figure 1D) were infected with vectors encoding two different shRNAs targeting MECP2 or shRNA targeting Luciferase as a control. Crystal violet staining was done 12 days post-infection, photographed and quantitated by OD595. Mean ±SD data from 3 independent viral infections (n =3) were analyzed using one-way ANOVA followed by post hoc
Dunnett’s multiple comparison test. Asterisks indicate statistically significant differences between shMECP2-infected cells and shLuciferase-infected cells from lung cancer lines: NCI-H1755 (***: p<0.0001 for shMECP2#1, and p<0.0001 for shMECP2#3'UTR), NCI-H23 (**: p=0.0019 for shMECP2#1, and p=0.0013 for shMECP2#3'UTR), NCI-H1437 (ns: non-significant, p=0.7948 for shMECP2#1 and p=0.6709 for shMECP2#3'UTR). Immunoblots for MECP2 show the effects of the indicated shRNAs.

Lower: Two triple negative breast cancer cell lines with MECP2 copy number gain and MECP2-overexpression, BT549 and MDA-MB468, and MECP2 non-overexpressing cell line ZR75-1 (for MECP2 protein expression in these lines, see Figure 1D) were infected with vectors encoding two different shRNAs targeting MECP2 or shRNA targeting Luciferase as a control. Crystal violet staining was done 12 days post-infection, photographed (above) and quantitated (below) by OD595. Mean ±SD data from 3 independent viral infections (n =3) were analyzed using one-way ANOVA followed by post hoc Dunnett’s multiple comparison test. Asterisks indicate statistically significant differences between shMECP2-infected cells and shLuciferase-infected cells from breast cancer lines: BT549 (****: p<0.0001 for shMECP2#1, and p<0.0001 for shMECP2#3'UTR), MDAMB468 (****: p<0.0001 for shMECP2#1, and p<0.0001 for shMECP2#3'UTR), ZR75-1 (ns: non-significant, p=0.3928 for shMECP2#1 and p=0.7986 for shMECP2#3'UTR). Immunoblots for MECP2 show the effects of the indicated shRNAs.

(F) NCI-H1755, an MECP2-overexpressing lung adenocarcinoma cell line used in 7A above, was infected with lentiviruses expressing the genes shown on the X axis, and then infected with the shMECP2#3'UTR (used in figure 4E above), or a control shRNA directed against luciferase. Cell growth was quantitated after 7 days by crystal violet (0.1%) staining of adherent cells followed by measurement of optical density of cell-associated
dye extracted. Mean ±SD data from 3 independent viral infections (n = 3) were analyzed using one-way ANOVA followed by post hoc Dunnett’s multiple comparison test. Asterisks indicate statistically significant differences between GFP- versus MECP2-mediated rescue of MECP2 knockdown (****: p < 0.0001 for MECP2 e1+e2; *: p = 0.0340 for MECP2 e2; ns: non-significant, p = 0.8970 for MECP2 e1).

(G) The MECP2-addicted triple negative breast cancer cell line MDAMB468 was infected with lentiviruses expressing either GFP or activated RAS (KRAS<sup>G12V</sup>), and then infected with an shRNA targeting the MECP2 3’UTR (the same as used in figures 4E and 4F) or an shRNA targeting Luciferase as a control. Cell growth was quantitated after 7 days by crystal violet (0.1%) staining of adherent cells followed by measurement of optical density of cell-associated dye extracted. Mean ±SD data from 3 independent viral infections (n = 3) were analyzed using unpaired two-tailed Student’s t test. Asterisks indicate statistically significant difference between GFP- versus KRAS<sup>V12</sup>-mediated rescue of MECP2 knockdown (****: p < 0.0001).
<table>
<thead>
<tr>
<th>Cancer Subset</th>
<th>Q-value</th>
<th>Overall Frequency of Amplification</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Cancers</td>
<td>2.4x10^{-24}</td>
<td>18%</td>
</tr>
<tr>
<td>All Epithelial</td>
<td>1.3x10^{-22}</td>
<td>20%</td>
</tr>
<tr>
<td>Ovarian</td>
<td>7.3x10^{-10}</td>
<td>38%</td>
</tr>
<tr>
<td>Triple Negative Breast</td>
<td>0.175</td>
<td>33%</td>
</tr>
<tr>
<td>Lung Adeno</td>
<td>1.5x10^{-6}</td>
<td>29%</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>0.01</td>
<td>28%</td>
</tr>
<tr>
<td>Lung Squamous</td>
<td>9.9x10^{-2}</td>
<td>25%</td>
</tr>
<tr>
<td>Cervical</td>
<td>8.8x10^{-4}</td>
<td>25%</td>
</tr>
<tr>
<td>Liver</td>
<td>0.085</td>
<td>24%</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.06</td>
<td>19%</td>
</tr>
<tr>
<td>Uterine</td>
<td>9.3x10^{-3}</td>
<td>17%</td>
</tr>
</tbody>
</table>
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy

Manish Neupane, Allison P. Clark, Serena Landini, et al.

Cancer Discov. Published OnlineFirst November 6, 2015.

Updated version

Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-15-0341

Supplementary Material

Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2015/11/11/2159-8290.CD-15-0341.DC1.html

Author Manuscript

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.